Zhi Jin Xu

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

John A. Smith, Michael M. Kitt, Alyn H. Morice et al. · The Lancet Respiratory Medicine · 2020 · 224 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Gefapixant in two randomised dose-escalation studies in chronic cough

John A. Smith, Michael M. Kitt, P. Butera et al. · European Respiratory Journal · 2020 · 135 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study

D. Gray Heppner, Tracy Kemp, Brian K. Martin et al. · The Lancet Infectious Diseases · 2017 · 121 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial

Princy Kumar, Margaret Johnson, Jean‐Michel Molina et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2021 · 54 citations · Full text

Pharmacy, Pharmacotherapy, Clinical Pharmacology +14

Changes in weight and BMI with first-line doravirine-based therapy

Chloe Orkin, Richard Elion, Melanie Thompson et al. · AIDS · 2020 · 44 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17